Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011824
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, live biotherapeutics, small molecules and complex macromolecules which are aimed for specific region in gastrointestinal tract(GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company has research and development facilities in New York, Indiana and California. Assembly is headquartered in Carmel, Indiana, the US.

Assembly Biosciences Inc (ASMB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Merger 11
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Licensing Agreements 12
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Equity Offering 17
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc – Key Competitors 29
Assembly Biosciences Inc – Key Employees 30
Assembly Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jul 28, 2017: Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 32
Jan 11, 2016: Assembly Biosciences Expands Senior Leadership Team 33
Product News 35
01/27/2016: Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel Technology Achieves Targeted Delivery to the Lower GI Tract 35
Clinical Trials 36
Sep 25, 2017: Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development 36
Nov 09, 2016: Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc, Key Competitors 29
Assembly Biosciences Inc, Key Employees 30
Assembly Biosciences Inc, Other Locations 31
Assembly Biosciences Inc, Subsidiaries 31

★海外企業調査レポート[Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Newhaven Hotels Limited:企業の戦略・SWOT・財務分析
    Newhaven Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Newhaven Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ascentage Pharma Group Corp Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Ascentage Pharma Group Corp Ltd (Ascentage Pharma) is a biopharmaceutical company that discovers and develops targeted small-molecule therapeutics for the treatment of cancers, hepatitis B and age-related diseases. The company’s pipeline product includes apoptosis compounds and kinase inhibi …
  • McAlister’s Corporation:企業の戦略・SWOT・財務情報
    McAlister’s Corporation - Strategy, SWOT and Corporate Finance Report Summary McAlister’s Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Algonquin Power & Utilities Corp:発電所・企業SWOT分析
    Algonquin Power & Utilities Corp - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Novo Nordisk A/S:戦略・SWOT・企業財務分析
    Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report Summary Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Comet Ridge Ltd (COI):企業の財務・戦略的SWOT分析
    Summary Comet Ridge Ltd (CRL) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company holds interests in Mahalo project located in the Denison trough area of Queensland's Bowen Basin near Rolleston. It also holds interest in PEL 6 …
  • Mitsui & Co., Ltd.:企業のM&A・事業提携・投資動向
    Mitsui & Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsui & Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Kiadis Pharma NV (KDS):企業の財務・戦略的SWOT分析
    Summary Kiadis Pharma NV (Kiadis) is a biopharmaceutical company that develops and markets cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company offers cellular products including ATIR101 and ATIR201 for infusion. Its ATIR101 lowers the risks …
  • WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • Northern Biologics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Northern Biologics Inc. (Northern Biologics) is a biotech company, which develops a portfolio of antibody therapies for treating cancer. The product pipeline of the company includes MSC-1, a first-in-class antibody that acts against leukemia inhibitory factor (LIF), which is a major immunosu …
  • Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野:企業M&A・提携分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive canna …
  • National Jewish Health-製薬・医療分野:企業M&A・提携分析
    Summary National Jewish Health (NJH), formerly National Jewish Medical and Research Center is a healthcare center that offers treatment of pulmonary, cardiac, immune and related disorders. The center offers services in the areas of allergy, asthma, cardiology, clinical immunology, COPD, environmenta …
  • Bashneft (BANE)-石油・ガス分野:企業M&A・提携分析
    Summary Bashneft is a vertically integrated oil and gas company. It operates in the oil and gas production, refining, petrochemical production, marketing and distribution of oil and petroleum products. It sales crude oil, petroleum products and petrochemical products to the domestic market. The comp …
  • Moody’s Corporation:企業の戦略・SWOT・財務情報
    Moody's Corporation - Strategy, SWOT and Corporate Finance Report Summary Moody's Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rostelecom:企業の戦略・SWOT・財務情報
    Rostelecom - Strategy, SWOT and Corporate Finance Report Summary Rostelecom - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • TMX Group Ltd (X):企業の財務・戦略的SWOT分析
    TMX Group Ltd (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Abeona Therapeutics Inc (ABEO)-医療機器分野:企業M&A・提携分析
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO …
  • Mediaset S.p.A. (MS):企業の財務・戦略的SWOT分析
    Mediaset S.p.A. (MS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Provenance Biopharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Provenance Biopharmaceuticals Corp (Provenance) is a biotechnology company that develops various novel immunotherapeutic drugs to treat cancer and other serious, life-threatening diseases. The company offers cancer drugs based on antibodies which include avastin, erbitux, hercepton, and ritu …
  • Kang Stem Biotech Co Ltd (217730):製薬・医療:M&Aディール及び事業提携情報
    Summary Kang Stem Biotech Co Ltd (Kang Stem Biotech) is a biopharmaceutical company that develops stem cell therapeutic products for the treatment of incurable diseases using umbilical cord blood-derived stem cells. The company’s stem cell therapy products include Furestem-AD for treating subacute a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆